Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma

Adamantinomatous craniopharyngioma (ACP) makes up between 6 and 8% of pediatric brain tumors and is the most common pediatric tumor arising in the sellar/suprasellar region of the brain. The 10-year survival for patients diagnosed with craniopharyngioma ranges between 64 and 92%, but complicating fa...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Sydney Grob, David M. Mirsky, Andrew M. Donson, Nathan Dahl, Nicholas K. Foreman, Lindsey M. Hoffman, Todd C. Hankinson, Jean M. Mulcahy Levy
Materialtyp: Artigo
Språk:Inglês
Publicerad: Frontiers Media S.A. 2019-08-01
Serie:Frontiers in Oncology
Ämnen:
craniopharyngioma
IL-6
tocilizumab
pediatric
bevacizumab
Länkar:https://www.frontiersin.org/article/10.3389/fonc.2019.00791/full
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk